MJFF have an article on kinetin [1] linked to PINK. See also the paper by Hertz et al.[2] where they write:

"we show that application of the KTP precursor kinetin to cells results in biologically significant increases in PINK1 activity, manifest as higher levels of Parkin recruitment to depolarized mitochondria, reduced mitochondrial motility in axons, and lower levels of apoptosis."

This would become hugely exciting if kinetin was shown to be a tyrosine kinase inhibitor, like nilotinib, the anti-cancer drug, which in lower doses is thought to have a potentially therapeutic effect on PD.

The effects described above would, in my opinion, only become visible after a few months, at best. So, although very welcome, I don't think that this explains the short-term benefits described.

Where do you get your oral kinetin from?

References:

[1] https://www.michaeljfox.org/foundati...kinson-disease

[2] "A neo-substrate that amplifies catalytic activity of Parkinson’s disease related kinase PINK1"
Nicholas T. Hertz,1,2,7 Amandine Berthet,3 Martin L. Sos,1 Kurt S. Thorn,6 Al L. Burlingame,5 Ken Nakamura,3,4 and Kevan M. Shokat
Cell. 2013 Aug 15; 154(4): 737–747
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950538/

John